Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Califf

Showing results (501-510 of 567) with videos related to

Pageof 57
Sort By:
The American Journal of Cardiology|May 30, 1998
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary ArteriesJ Hochrein, F Sun, K S Pieper, et al.
Journal of the American College of Cardiology|July 14, 2001
Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-upK P Alexander, L K Newby, A S Hellkamp, et al.
Annals of Internal Medicine|October 6, 1997
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrumentH P Selker, J L Griffith, J R Beshansky, et al.
Circulation|December 6, 2001
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromesM Roffi, D P Chew, D Mukherjee, et al.
Circulation|June 20, 2001
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudyL K Newby, E M Ohman, R H Christenson, et al.
The New England Journal of Medicine|July 29, 1999
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting InvestigatorsA M Lincoff, R M Califf, D J Moliterno, et al.
The American Journal of Cardiology|August 29, 2001
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS)C M O'Connor, W A Gattis, A S Hellkamp, et al.
Circulation|August 16, 2000
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic diseaseR A Harrington, P W Armstrong, C Graffagnino, et al.
Circulation|November 3, 1998
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa InvestigatorsL K Newby, R H Christenson, E M Ohman, et al.
Circulation|August 26, 1998
Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of TreatmentsH M Krumholz, R S Phillips, M B Hamel, et al.
Pageof 57

Showing results (501-510 of 567) with videos related to

Sort By:
Pageof 57
The American Journal of Cardiology|May 30, 1998
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary ArteriesJ Hochrein, F Sun, K S Pieper, et al.
Journal of the American College of Cardiology|July 14, 2001
Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-upK P Alexander, L K Newby, A S Hellkamp, et al.
Annals of Internal Medicine|October 6, 1997
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrumentH P Selker, J L Griffith, J R Beshansky, et al.
Circulation|December 6, 2001
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromesM Roffi, D P Chew, D Mukherjee, et al.
Circulation|June 20, 2001
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudyL K Newby, E M Ohman, R H Christenson, et al.
The New England Journal of Medicine|July 29, 1999
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting InvestigatorsA M Lincoff, R M Califf, D J Moliterno, et al.
The American Journal of Cardiology|August 29, 2001
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS)C M O'Connor, W A Gattis, A S Hellkamp, et al.
Circulation|August 16, 2000
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic diseaseR A Harrington, P W Armstrong, C Graffagnino, et al.
Circulation|November 3, 1998
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa InvestigatorsL K Newby, R H Christenson, E M Ohman, et al.
Circulation|August 26, 1998
Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of TreatmentsH M Krumholz, R S Phillips, M B Hamel, et al.
Pageof 57